drugset / Trial / NCT01049178

Randomized Controlled Trial of Silymarin in Asthma

NCT01049178 ↗

Phase 2/3 Withdrawn Vanderbilt University
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine if intake of the antioxidant enzyme inducer, silymarin, will improve lung function and symptom scores in participants with asthma.

Timeline

Start
2010-09
Primary completion
2010-09
Completion
2010-09

Outcome

Outcome not reported

Stopped (Business): “Lack of funding”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Silymarin Traditional medicine (herbal / TCM) 140 mg Oral
Subject Silymarin Traditional medicine (herbal / TCM) 420 mg Oral
Subject Silymarin Traditional medicine (herbal / TCM) 700 mg Oral

Indications